Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08ALK
|
|||
| Former ID |
DNC000439
|
|||
| Drug Name |
Cisatracurium
|
|||
| Synonyms |
Cisatracurium Besylate; Cisatracurium Besylate Preservative Free; Nimbex; Nimbex Preservative Free
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Muscle spasm [ICD-11: MB47.3] | Approved | [1] | |
| Company |
Abbvie Inc
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C53H72N2O12+2
|
|||
| Canonical SMILES |
C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
|
|||
| InChI |
1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
|
|||
| InChIKey |
YXSLJKQTIDHPOT-LJCJQEJUSA-N
|
|||
| CAS Number |
CAS 96946-41-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7847824, 7978533, 8188345, 11113043, 12014680, 43119947, 46506666, 49835824, 50065421, 56268482, 57314899, 75324009, 103770624, 104326905, 117384760, 124403636, 126607198, 126665888, 134222121, 134337515, 134339864, 135019778, 137006710, 143504269, 160963910, 162181993, 164831244, 175266594, 175269717, 175612222, 198957787, 210274894, 210280529, 224405114, 226425863, 252215160, 252359546
|
|||
| ChEBI ID |
CHEBI:140621
|
|||
| ADReCS Drug ID | BADD_D00473 ; BADD_D02422 | |||
| SuperDrug ATC ID |
M03AC11
|
|||
| SuperDrug CAS ID |
cas=096946428
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholinergic receptor unspecific (CHR) | Target Info | Antagonist | [2] |
| Neuronal acetylcholine receptor alpha-2 (CHRNA2) | Target Info | Antagonist | [3], [4] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Nicotinic acetylcholine receptor signaling pathway | |||
| Reactome | Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | |||
| Highly calcium permeable nicotinic acetylcholine receptors | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92. | |||
| REF 3 | Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. | |||
| REF 4 | Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.